Bipolar Affective Disorder

11/10/11 2:51 PM

Bipolar Affective Disorder

Author: Stephen Soreff, MD; Chief Editor: Iqbal Ahmed, MBBS, FRCPsych (UK) more... Updated: Oct 6, 2011

Background
Bipolar disorder, or manic-depressive illness (MDI), is one of the most common, severe, and persistent mental illnesses. Bipolar disorder is a serious lifelong struggle and challenge.[1] Bipolar disorder is characterized by periods of deep, prolonged, and profound depression that alternate with periods of an excessively elevated or irritable mood known as mania. The symptoms of mania include a decreased need for sleep, pressured speech, increased libido, reckless behavior without regard for consequences, grandiosity, and severe thought disturbances, which may or may not include psychosis. Between these highs and lows, patients usually experience periods of higher functionality and can lead a productive life. Bipolar disorder constitutes 1 pole of a spectrum of mood disorders that includes including bipolar I (BPI), bipolar II (BPII), cyclothymia (oscillating high and low moods), and major depression. BPI, also referred to as classic manic-depression, is characterized by distinct episodes of major depression contrasting vividly with episodes of mania, which lead to severe impairment of function. In comparison, BPII is a milder disorder that consists of depression alternating with periods of hypomania. Hypomania may be thought of as a less severe form of mania that does not include psychotic symptoms or lead to major impairment of social or occupational function. Go to Pediatric Bipolar Affective Disorder for complete information on this topic.

Case history
At the age of 25, D.A.K., a postgraduate student in chemistry, found himself at the emergency department (ED) of the university hospital, where the campus police had brought him. He had been working late at the laboratory alone when the police came. He had been awake for the past 4 days working on an experiment that he believed would save the world. D.A.K.s professors had voiced concerns as the often quiet and well-mannered student had recently begun to take over the class discussions and interrupt lectures. More remarkable than the behavior itself was the change it represented. In the preceding semester, D.A.K. had been uncharacteristically quiet and withdrawn. Many suspected that he was depressed, but they could find no apparent reason for his behavior. Then he isolated himself from friends and family and stopped seeing his girlfriend of 2 years. D.A.K. had a family history of depression on his mothers side, with a grandmother who had received electroconvulsive therapy (ECT) years ago in a state hospital. On his fathers side, his uncle had received lithium and had been diagnosed with manic depression. A vague history of colorblindness was also noted. D.A.K. had a younger sister who was often described as moody. In the ED, D.A.K. was belligerent, talked rapidly but coherently, and demanded to return to the laboratory so that he could save his experiment and thus the world. He wanted a lawyer and denied being suicidal but threatened those who, he claimed, were standing in his way. He accused the faculty of being against him, threatened legal action against those incarcerating him, denied hallucinations but clearly saw himself in highly grandiose terms, was orientated times 3, had good recall, and was colorful and verbose in his response to proverbs. No history of drug or alcohol use was noted, except for a large consumption of coffee in the preceding several weeks. He had no obvious medical problems. D.A.K. kept demanding to leave and return to the laboratory to save everyone. He was a huge challenge to the
http://emedicine.medscape.com/article/286342-overview Page 1 of 10

Bipolar Affective Disorder

11/10/11 2:51 PM

emergency physicians, who could not wait for the psychiatric resident to arrive.

Pathophysiology
The pathophysiology of bipolar disorder has not been determined, and no objective biologic markers correspond definitively with the disease state. However, twin, family, and adoption studies all indicate that bipolar disorder has a genetic component. In fact, first-degree relatives of a person with bipolar disorder are approximately 7 times more likely to develop bipolar disorder than the rest of the population. The genetic component of bipolar disorder appears to be complex: the disorder is likely to be caused by multiple different common disease alleles, each of which contributes a relatively low degree of risk on its own. Such disease genes can be difficult to find without very large sample sizes, on the order of thousands of subjects. Fortunately, 4 genome-wide association studies of large samples of subjects with bipolar disorder have now been published,[2, 3, 4, 5] and a collaborative analysis of the last 3 studies give combined support for 2 particular genes, ANK3 (ankyrin G) and CACNA1C (alpha 1C subunit of the L-type voltage-gated calcium channel) in a sample of 4,387 cases and 6,209 controls.[5] ANK3 is an adaptor protein found at axon initial segments that regulates the assembly of voltage-gated sodium channels. Both ANK3 and subunits of the calcium channel are down-regulated in mouse brain in response to lithium, which indicates a possible therapeutic mechanism of action of 1 of the most effective treatments for bipolar disorder.[6] The first genome-wide association study of bipolar disorder used a much smaller sample size,[2] an initial sample of 461 patients with bipolar disorder from the National Institute of Mental Health (NIMH) consortium and a follow-up sample of 563 patients collected in Germany. Nevertheless, this study remains of interest, in that the strongest association signals were detected in genes also involved in biochemical pathways regulated by lithium. The strongest hit was at a marker within the first intron of diacylglycerol kinase eta (DGKH) gene. DGKH is a key protein in the lithium-sensitive phosphatidyl inositol pathway. Three of the other associated genes in this study also interact with the Wnt signaling pathway upstream and downstream of glycogen synthase kinase 3-beta (GSK3). Lithium-mediated inhibition of GSK3 is thought to result in downregulation of molecules involved in cell death and upregulation of neuroprotective factors. Additionally, GSK3 is a central regulator of the circadian clock, and lithium-mediated modulation of circadian periodicity is thought to be a critical component of lithiums therapeutic effect. In fact, another major coup for bipolar disorder research has been the finding that a dominant-negative mutation in the CLOCK gene normally contributing to circadian periodicity in humans results in maniclike behavior in mice.[7] Manic behavior in CLOCK mutant mice includes hyperactivity, decreased sleep, reduced anxiety, and an increased response to cocaine. The latter finding also provides a shared biologic basis for the high rate of substance abuse observed in clinical populations of subjects with bipolar disorder. Furthermore, the experimenters were able to abolish the manic behaviors by rescuing expression of normal CLOCK specifically in the ventral tegmental area of the mouse brain.[8] This area is rich in D2 receptors. Joseph Coyle hypothesizes in his commentary in the paper on the same issue that the efficacy of atypical antipsychotics in acute mania might, in part, be achieved by their ability to lower activity in neurons specifically within the ventral tegmental area. Findings from gene expression studies comparing postmortem brain tissue from persons with bipolar disorder with tissue from control subjects have yielded exciting new insights into the pathophysiology of the disorder. In particular, levels of expression of oligodendrocyte-myelin-related genes appear to be decreased in brain tissue from persons with bipolar disorder.[9, 10, 11, 12, 13] Oligodendrocytes produce myelin membranes that wrap around and insulate axons to permit the efficient conduction of nerve impulses in the brain. Therefore, loss of myelin is thought to disrupt communication between neurons, leading to some of the thought disturbances observed in bipolar disorder and related illnesses. Brain imaging studies of persons with bipolar disorder also show abnormal myelination in several brain regions associated with this illness.

http://emedicine.medscape.com/article/286342-overview

Page 2 of 10

Bipolar Affective Disorder

11/10/11 2:51 PM

A meta-analyses by Houenou et al found decreased activation and diminution of gray matter in a cortical-cognitive brain network, which has been associated with the regulation of emotions in patients with bipolar disorder. An increased activation in ventral limbic brain regions that mediate the experience of emotions and generation of emotional responses was also discovered. This provides evidence for functional and anatomical alterations in bipolar disorder in brain networks associated with the experience and regulation of emotions.[14] Interestingly, gene expression and neuroimaging studies of persons with schizophrenia and major depression also demonstrate similar findings, indicating that mood disorders and schizophrenia may share some biologic underpinnings, possibly related to psychosis. These types of data may also lead to the future revision of psychiatric diagnostic manuals based on a new understanding of the etiology of these disorders. The National Institutes of Health (NIH) report on recent genome-wide association studies demonstrated that bipolar disorder and schizophrenia could indeed share common susceptibility genes on chromosome 6.[15] These genes are located in a section of the chromosome that contains genes involved in immunity and controlling how and when genes turn on and off. This connection can help explain the link between environmental stress and schizophrenia and possibly bipolar disorder. Another approach to delineating the pathophysiology of bipolar disorder involves studying changes in gene expression induced in rodent brains after administration of pharmacologic agents used to treat bipolar disorder. For example, investigators have demonstrated that 2 chemically unrelated drugs (lithium and valproate) used to treat bipolar disorder both upregulate the expression of the cytoprotective protein Bcl-2 in the frontal cortex and the hippocampus of rat brains. A postmortem study by Konradi et al of the hippocampus in both patients with bipolar disorder and healthy persons found that the 2 groups did not differ in the total number of hippocampal neurons.[16] However, patients with bipolar disorder had reduced volume of nonpyramidal cell layers, reduced number of somatostatin-positive and parvalbumin positive neurons, and reduced somal volume in cornu ammonis sector 2/3, and reduced messenger RNA levels for somatostatin, parvalbumin, and glutamic acid decarboxylase 1. The findings suggest alteration of hippocampal interneurons in patients with bipolar disorder that likely leads to hippocampal dysfunction. Neuroimaging studies of individuals with bipolar disorder or other mood disorders also suggest evidence of cell loss or atrophy in these same brain regions. Thus, another suggested cause of bipolar disorder is damage to cells in the critical brain circuitry that regulates emotion. According to this hypothesis, mood stabilizers and antidepressants are thought to alter mood by stimulating cell survival pathways and increasing levels of neurotrophic factors to improve cellular resiliency. In 2008, Mathew et al published a review of novel drugs and therapeutic targets for severe mood disorders that focus on increasing neuroplasticity and cellular resiliency.[17] Post et al proposed a mechanism involving electrophysiologic kindling and behavioral sensitization processes, which resonates with the neuronal injury hypothesis.[18] They asserted that a person who is susceptible to bipolar disorder experiences an increasing number of minor neurologic insultsfrom drugs of abuse, stress-related excessive glucocorticoid stimulation, or other factorsthat eventually result in mania.[18] Sufficient brain damage might persist to cause mania to recur even with no or minor environmental or behavioral stressors. This type of formulation helps explain the effective role of anticonvulsant medications (eg, carbamazepine and valproate) in the prevention of the highs and lows of bipolar disorder. It also supports clinical observations that the more episodes a person experiences, the more he or she will have in the future, underscoring the need for longterm treatment.

Etiology
A number of factors contribute to bipolar disorder, including genetic, biochemical, psychodynamic, and environmental factors.

Genetic factors
As noted (see Pathophysiology), bipolar disorder, especially BPI, has a major genetic component, with the involvement of the ANK3,CACNA1C, and CLOCK genes.[2, 3, 4, 5, 7] The evidence indicating a genetic role in bipolar disorder takes several forms.

http://emedicine.medscape.com/article/286342-overview

Page 3 of 10

Bipolar Affective Disorder

11/10/11 2:51 PM

First-degree relatives of people with BPI are approximately 7 times more likely to develop BPI than the general population. Remarkably, offspring of a parent with bipolar disorder have a 50% chance of having another major psychiatric disorder. Twin studies demonstrate a concordance of 33-90% for BPI in identical twins. Adoption studies prove that a common environment is not the only factor that makes bipolar disorder occur in families. Children whose biologic parents have either BPI or a major depressive disorder remain at increased risk of developing an affective disorder, even if they are reared in a home with adopted parents who are not affected. For more information on bipolar disorder in children, see New Findings in Childhood Bipolar Disorder. An interesting finding in psychiatric genetics heralds the future revision of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) according to an etiologic rather than descriptive basis. Using probands from the Maudsley Twin Register in London, Cardno and colleagues showed that schizophrenic, schizoaffective, and manic syndromes share genetic risk factors and that the genetic liability was the same for schizoaffective disorder as for the other 2 syndromes.[19] This finding suggests an independent genetic liability for psychosis shared by both mood and schizophrenia spectrum disorders, as Berrettini[20] previously speculated. A study by Tsuang et al further indicates the genetic contribution to manic-depressive illness with psychotic features. Their findings show the link between schizophrenia and bipolar disorder.[21] As noted (see Pathophysiology), gene expression studies also demonstrate that persons with bipolar disorder, major depression, and schizophrenia share similar decreases in the expression of oligodendrocyte-myelin-related genes and abnormalities of white matter in various brain regions.

Biochemical factors
Multiple biochemical pathways likely contribute to bipolar disorder, which is why detecting one particular abnormality is difficult. A number of neurotransmitters have been linked to this disorder, largely based on patients responses to psychoactive agents. Evidence is mounting of the contribution of glutamate to both bipolar disorder and major depression. A postmortem study of the frontal lobes with both these disorders revealed that the glutamate levels were increased.[22] The blood pressure drug reserpine, which depletes catecholamines from nerve terminals, was noted incidentally to cause depression. This led to the catecholamine hypothesis, which holds that an increase in epinephrine and norepinephrine causes mania and a decrease in epinephrine and norepinephrine causes depression. Drugs like cocaine, which also act on this neurotransmitter system, exacerbate mania. Other agents that exacerbate mania include L-dopa, which implicates dopamine and serotonin-reuptake inhibitors, which in turn implicate serotonin. Calcium channel blockers have been used to treat mania, which also may result from a disruption of calcium regulation in neurons. The proposed disruption of calcium regulation may be caused by various neurologic insults, such as excessive glutaminergic transmission or ischemia. Interestingly, valproate specifically up-regulates expression of a calcium chaperone protein, GRP 78, which may be one of its chief mechanisms of cellular protection. Hormonal imbalances and disruptions of the hypothalamic-pituitary-adrenal axis involved in homeostasis and the stress response may also contribute to the clinical picture of bipolar disorder. Tricyclic antidepressants can trigger mania.[23]

Psychodynamic factors
Many practitioners see the dynamics of manic-depressive illness as being linked through a single common pathway. They see the depression as the manifestation of losses (ie, the loss of self-esteem and the sense of worthlessness). Therefore, the mania serves as a defense again st the feelings of depression. Melanie Klein was one of the major proponents of this formulation. A study by Barnett et al found that personality disturbances in extraversion, neuroticism, and openness are often noted in patients
http://emedicine.medscape.com/article/286342-overview Page 4 of 10

Bipolar Affective Disorder

11/10/11 2:51 PM

with bipolar disorder and may be enduring characteristics.[24]

Environmental factors
In some instances, the cycle may be directly linked to external stresses or the external pressures may serve to exacerbate some underlying genetic or biochemical predisposition. Pregnancy is a particular stress for women with a manic-depressive illness history and increases the possibility of postpartum psychosis.[25] Because of the nature of their work, certain individuals have periods of high demands followed by periods of few requirements. For example, a landscaper and gardener was busy in the spring, summer, and fall but relatively inactive during the winter, except for plowing snow. Thus, he appeared manic for a good part of the year and then would crash and hibernate for the cold months.

Epidemiology
United States statistics
The lifelong prevalence of bipolar disorder in the United States has been noted to range from 1% to 1.6%. Studies indicate differences in lifetime prevalence estimates for BPI, BPII, and subthreshold bipolar disorders: 1.0% for BPI, 1.1% for BPII, and 2.4-4.7% for subthreshold bipolar disorders.[9]

International statistics
Lifelong prevalence rate is 0.3-1.5%. In cross-sectional, face-to-face household surveys of more than 61,000 adults across 11 countries, Merikangas et al, using the World Mental Health version of the World Health Organization Composite International Diagnostic Interview, version 3.0, determined that the aggregate lifetime prevalences were 0.6% for bipolar I disorder, 0.4% for bipolar II disorder, 1.4% for subthreshold bipolar disorder, and 2.4% for bipolar spectrum.[26]

Age-related differences in incidence

The age of onset of bipolar disorder varies greatly. For both BPI and BPII, the age range is from childhood to 50 years, with a mean age of approximately 21 years. Most cases commence when individuals are aged 15-19 years. The second most frequent age range of onset is 20-24 years. Some patients diagnosed with recurrent major depression may indeed have bipolar disorder and go on to develop their first manic episode when older than 50 years. They may have a family history of bipolar disorder. However, for most patients, the onset of mania in people older than 50 years should lead to an investigation for medical or neurologic disorders, such as cerebrovascular disease. Go to Pediatric Bipolar Affective Disorder for complete information on this topic.

Sex-related differences in incidence

BPI occurs equally in both sexes; however, rapid-cycling bipolar disorder (4 or more episodes a year) is more common in women than in men. The incidence of BPII is higher in females than in males.

Race-related differences in incidence

No racial predilection exists. However, a point of historical interest is that clinicians often tend to consider populations of African Americans and Hispanics as more likely to be diagnosed with schizophrenia than with affective disorders and bipolar disorder.

Prognosis
Bipolar disorder has significant morbidity and mortality rates. In the United States during the early part of the 1990s, the cost of lost productivity resulting from this bipolar disorder was estimated at approximately $15.5 billion annually. Approximately 25-50% of individuals with bipolar disorder attempt suicide, and 11% actually commit
http://emedicine.medscape.com/article/286342-overview Page 5 of 10

Bipolar Affective Disorder

11/10/11 2:51 PM

suicide. Additionally, a recent study from the United Kingdom suggests that for patients with bipolar disorder, mortality one year after hospital discharge was also higher than that of the general population for natural causes, chiefly respiratory and circulatory disorders.[27] Patients with BPI fare worse than patients with a major depression. Within the first 2 years after the initial episode, 40-50% of patients experience another manic attack. Only 50-60% of patients with BPI who are on lithium gain control of their symptoms. In 7% of these patients, symptoms do not recur, 45% of patients experience more episodes, and 40% go on to have a persistent disorder. Often, the cycling between depression and mania accelerates with age. Factors suggesting a worse prognosis include the following: Poor job history Alcohol abuse Psychotic features Depressive features between periods of mania and depression Evidence of depression Male sex Factors suggesting a better prognosis include the following: Manic phases (short in duration) Late age of onset Few thoughts of suicide Few psychotic symptoms Few medical problems

Patient Education
Treatment of patients with bipolar disorder involves initial and ongoing patient education. To this end, a strong therapeutic alliance is essential. Educational efforts must be directed not only toward the patient but also toward their family and support system. Furthermore, evidence continues to mount that these educational efforts not only increase patient compliance and their knowledge of the disease, but also their quality of life.[28] An explanation of the biology of the disease must be provided. This decreases feelings of guilt and promotes medication compliance. Information should be provided on how to monitor the illness in terms of an appreciation of the early warning signs, reemergence, and symptoms. Recognition of changes can serve as a powerful preventive step. Education must also encompass the dangers of stressors. Helping the individual identify and work with stressors provides a critical aspect of patient and family awareness. Efforts should be made to educate the patient about relapses within the total context of the disorder. Individual stories help patients and families. NIMH has a story of a person with manic-depressive illness that can help the patient see the struggle and challenge from another perspective.[29] Others have written about their family struggles and challenges.[30] Important resources for patients and families to gain information on dealing with manic-depressive illness include the following: National Institute of Mental Health (NIMH) - Public Information and Communications Branch, 6001 Executive Blvd, Rm 8184, MSC 9663, Bethesda, MD 20892-9663; phone, 301-443-4513 (local) or 866-6156464 (toll-free); fax, 301-443-4279 Fax Back System, Mental Health FAX4U 301-443-5158; e-mail: nimhinfo@nih.gov Child & Adolescent Bipolar Foundation - 1000 Skokie Blvd, Suite 570, Wilmette, IL 60091; phone, 847-2568525; e-mail, cabf@bpkids.org Depression and Related Affective Disorders Association (DRADA) - 2330 West Joppa Rd, Suite 100, Lutherville, MD 21093; phone, 410-583-2919; e-mail, drada@jhmi.edu
http://emedicine.medscape.com/article/286342-overview Page 6 of 10

Bipolar Affective Disorder

11/10/11 2:51 PM

National Alliance on Mental Illness (NAMI) - Colonial Place Three, 2107 Wilson Blvd, Suite 300, Arlington, VA 22201-3042; phone, 703-524-7600 (local) or 800-950-NAMI (6264) (toll-free); fax, 703-524-9094 Depression & Bipolar Support Alliance (DBSA) - 730 North Franklin St, Suite 501, Chicago, IL 60610-7224; phone, 312-642-0049 (local) or 800-826-3632 (toll-free); fax, 312-642-7243 International Foundation for Research and Education on Depression (iFred) - 2017-D Renard Court, Annapolis, MD 21401; phone, 401-268-0044; fax, 443-782-0739; e-mail, info@ifred.org Mental Health America (MHA) - 2000 North Beauregard St, 6th Floor, Alexandria, VA 22311; phone, 703684-7722 (local) or 800-969-6642 (toll-free); TTY, 800-443-5959; fax, 703-684-7722 For patient education resources, see the Depression Center, as well as Depression and Bipolar Disorder.

Contributor Information and Disclosures

Author Stephen Soreff, MD President of Education Initiatives, Nottingham, NH; Faculty, Metropolitan College of Boston University, Boston, MA Stephen Soreff, MD is a member of the following medical societies: American College of Mental Health Administration and American Psychosomatic Society Disclosure: Nothing to disclose. Coauthor(s) Lynne Alison McInnes, MD Associate Clinical Professor of Psychiatry, University of California, San Francisco, School of Medicine; Associate Adjunct Professor of Psychiatry and Genetics and Genomic Sciences, Department of Psychiatry and Human Genetics, Mount Sinai School of Medicine Lynne Alison McInnes, MD is a member of the following medical societies: Alpha Omega Alpha, American Psychiatric Association, and American Society of Human Genetics Disclosure: Nothing to disclose. Specialty Editor Board Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference Disclosure: Medscape Salary Employment Chief Editor Iqbal Ahmed, MBBS, FRCPsych (UK) Faculty, Department of Psychiatry, Tripler Army Medical Center; Clinical Professor of Psychiatry, Clinical Professor of Geriatric Medicine, University of Hawaii, John A Burns School of Medicine Iqbal Ahmed, MBBS, FRCPsych (UK) is a member of the following medical societies: Academy of Psychosomatic Medicine, American Association for Geriatric Psychiatry, American Neuropsychiatric Association, American Psychiatric Association, American Society of Clinical Psychopharmacology, and Royal College of Psychiatrists Disclosure: Nothing to disclose.

References
1. Bowden C, Singh V. Long-term Management of Bipolar Disorder. Available at http://www.medscape.com/viewprogram/2686. Accessed Dec 31, 2003. 2. Baum AE, Akula N, Cabanero M, Cardona I, Corona W, Klemens B, et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry. Feb 2008;13(2):197-207. [Medline]. [Full Text]. 3. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. Jun 7 2007;447(7145):661-78. [Medline]. [Full Text].
http://emedicine.medscape.com/article/286342-overview Page 7 of 10

Bipolar Affective Disorder

11/10/11 2:51 PM

4. Sklar P, Smoller JW, Fan J, Ferreira MA, Perlis RH, Chambert K, et al. Whole-genome association study of bipolar disorder. Mol Psychiatry. Jun 2008;13(6):558-69. [Medline]. 5. Ferreira MA, O'Donovan MC, et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet. Sep 2008;40(9):1056-8. [Medline]. [Full Text]. 6. McQuillin A, Rizig M, Gurling HM. A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder. Pharmacogenet Genomics. Aug 2007;17(8):605-17. [Medline]. 7. Post RM, Speer AM, Hough CJ, Xing G. Neurobiology of bipolar illness: implications for future study and therapeutics. Ann Clin Psychiatry. Jun 2003;15(2):85-94. [Medline]. 8. Roybal K, Theobold D, Graham A, DiNieri JA, Russo SJ, Krishnan V, et al. Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci U S A. Apr 10 2007;104(15):6406-11. [Medline]. [Full Text]. 9. Calabrese JR. Overview of patient care issues and treatment in bipolar spectrum and bipolar II disorder. J Clin Psychiatry. Jun 2008;69(6):e18. [Medline]. 10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, DSM-IV-TR. Washington, DC: 2000. 11. Frye MA. Diagnostic dilemmas and clinical correlates of mixed states in bipolar disorder. J Clin Psychiatry. May 2008;69(5):e13. [Medline]. 12. Adler CM, Holland SK, Schmithorst V, Wilke M, Weiss KL, Pan H, et al. Abnormal frontal white matter tracts in bipolar disorder: a diffusion tensor imaging study. Bipolar Disord. Jun 2004;6(3):197-203. [Medline]. 13. Aston C, Jiang L, Sokolov BP. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol Psychiatry. Mar 2005;10(3):309-22. [Medline]. 14. Houenou J, Frommberger J, Carde S, et al. Neuroimaging-based markers of bipolar disorder: Evidence from two meta-analyses. J Affect Disord. Aug 2011;132(3):344-55. [Medline]. 15. NIH News. Schizophrenia and Bipolar Disorder Share Genetic Roots. National Institutes of Health. Available at http://www.nih.gov/news/health/jul2009/nimh-01.htm. Accessed August 26, 2009. 16. Konradi C, Zimmerman EI, Yang CK, Lohmann KM, Gresch P, Pantazopoulos H, et al. Hippocampal interneurons in bipolar disorder. Arch Gen Psychiatry. Apr 2011;68(4):340-50. [Medline]. 17. Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. Aug 2008;33(9):2300. [Medline]. 18. Fagiolini A. Medical monitoring in patients with bipolar disorder: a review of data. J Clin Psychiatry. Jun 2008;69(6):e16. [Medline]. 19. Cardno AG, Rijsdijk FV, Sham PC, Murray RM, McGuffin P. A twin study of genetic relationships between psychotic symptoms. Am J Psychiatry. Apr 2002;159(4):539-45. [Medline]. 20. Berrettini WH. Are schizophrenic and bipolar disorders related? A review of family and molecular studies. Biol Psychiatry. Sep 15 2000;48(6):531-8. [Medline]. 21. Tsuang MT, Taylor L, Faraone SV. An overview of the genetics of psychotic mood disorders. J Psychiatr Res. Jan 2004;38(1):3-15. [Medline]. 22. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry. Dec 1 2007;62(11):1310-6. [Medline]. 23. Lepping P, Menkes DB. Abuse of dosulepin to induce mania. Addiction. Jul 2007;102(7):1166-7. [Medline]. 24. Barnett JH, Huang J, Perlis RH, et al. Personality and bipolar disorder: dissecting state and trait associations between mood and personality. Psychol Med. Aug 2011;41(8):1593-604. [Medline].
http://emedicine.medscape.com/article/286342-overview Page 8 of 10

Bipolar Affective Disorder

11/10/11 2:51 PM

25. Chaudron LH, Pies RW. The relationship between postpartum psychosis and bipolar disorder: a review. J Clin Psychiatry. Nov 2003;64(11):1284-92. [Medline]. 26. Merikangas KR, Jin R, He J-P, et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry. 2011;68(3):241-251. 27. Hoang U, Stewart R, Goldacre MJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. BMJ. Sep 13 2011;343:d5422. [Medline]. 28. Dogan S, Sabanciogullari S. The effects of patient education in lithium therapy on quality of life and compliance. Arch Psychiatr Nurs. Dec 2003;17(6):270-5. [Medline]. 29. National Institute of Mental Health. A story of bipolar disorder (manic-depressive illness). Available at http://www.nimh.nih.gov/publicat/bipolstory03.cfm. Accessed Dec 30, 2003. 30. Webb M. The Years of Silence Are Past: My Father's Life With Bipolar Disorder. Am J Psychiatry. Dec 1 2003;160(12):2257. 31. Journal of Affective Disorders. Misdiagnosing bipolar disorder - Do clinicians show heuristic biases?. May 2011;130(3):405-12. [Medline]. 32. Keck PE Jr. Evaluating Treatment Decisions in Bipolar Depression. Available at http://www.medscape.com/viewprogram/2571. Accessed Dec 30, 2003. 33. Hong CJ, Huo SJ, Yen FC, Tung CL, Pan GM, Tsai SJ. Association study of a brain-derived neurotrophicfactor genetic polymorphism and mood disorders, age of onset and suicidal behavior. Neuropsychobiology. 2003;48(4):186-9. [Medline]. 34. Ilgen MA, Bohnert AS, Ignacio RV, McCarthy JF, Valenstein MM, Kim HM, et al. Psychiatric diagnoses and risk of suicide in veterans. Arch Gen Psychiatry. Nov 2010;67(11):1152-8. [Medline]. 35. Bellivier F, Yon L, Luquiens A, et al. Suicidal attempts in bipolar disorder: results from an observational study (EMBLEM). Bipolar Disord. Jun 2011;13(4):377-386. [Medline]. 36. Fazel S, Lichtenstein P, Grann M, Goodwin GM, Lngstrm N. Bipolar disorder and violent crime: new evidence from population-based longitudinal studies and systematic review. Arch Gen Psychiatry. Sep 2010;67(9):931-8. [Medline]. 37. Saarni SI, Vierti S, Perl J, Koskinen S, Lnnqvist J, Suvisaari J. Quality of life of people with schizophrenia, bipolar disorder and other psychotic disorders. Br J Psychiatry. Nov 2010;197:386-94. [Medline]. 38. Fiedorowicz JG, Endicott J, Leon AC, Solomon DA, Keller MB, Coryell WH. Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry. Jan 2011;168(1):40-8. [Medline]. [Full Text]. 39. Leibenluft E. Severe mood dysregulation, irritability, and the diagnostic boundaries of bipolar disorder in youths. Am J Psychiatry. Feb 2011;168(2):129-42. [Medline]. 40. McIntyre RS, Soczynska JK, Beyer JL, Woldeyohannes HO, Law CW, Miranda A, et al. Medical comorbidity in bipolar disorder: re-prioritizing unmet needs. Curr Opin Psychiatry. Jul 2007;20(4):406-16. [Medline]. 41. Bradford DW, Kim MM, Braxton LE, Marx CE, Butterfield M, Elbogen EB. Access to medical care among persons with psychotic and major affective disorders. Psychiatr Serv. Aug 2008;59(8):847-52. [Medline]. 42. Bauer M, Alda M, Priller J, Young LT. Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. Pharmacopsychiatry. Nov 2003;36 Suppl 3:S250-4. [Medline]. 43. Ansari A, Osser DN. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on bipolar depression. Harv Rev Psychiatry. 2010;18(1):36-55. [Medline]. 44. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, et al. A randomized add-on
http://emedicine.medscape.com/article/286342-overview Page 9 of 10

Bipolar Affective Disorder

11/10/11 2:51 PM

trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. Aug 2010;67(8):793-802. [Medline]. [Full Text]. 45. Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry. Feb 2011;72(2):156-67. [Medline]. 46. Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry. Jul 2011;199:57-63. [Medline]. 47. Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. Jan 30 2010;375(9712):385-95. [Medline]. 48. Smith LA, Cornelius V, Warnock A, Bell A, Young AH. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord. Jun 2007;9(4):394-412. [Medline]. 49. Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. Aug 16 2011;[Medline]. 50. Hamrin V, Iennaco JD. Psychopharmacology of pediatric bipolar disorder. Expert Rev Neurother. Jul 2010;10(7):1053-88. [Medline]. 51. Gutman DA, Nemeroff C. Atypical Antipsychotics in Bipolar Disorder. Medscape. Available at http://www.medscape.com/viewarticle/554128. Accessed June 27, 2007. 52. Brooks JO 3rd, Goldberg JF, Ketter TA, Miklowitz DJ, Calabrese JR, Bowden CL, et al. Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the Systematic Treatment Enhancement Program for Bipolar Disorder. J Clin Psychiatry. Feb 2011;72(2):240-7. [Medline]. 53. Susan Jeffrey. FDA Warns of Aseptic Meningitis Risk With Lamotrigine. FDA Warns of Aseptic Meningitis Risk With Lamotrigine. Available at http://www.medscape.com/viewarticle/726845? src=ddd&uac=41752PN. Accessed August 12, 2010. 54. Sarris J, Mischoulon D, Schweiter I. Omega-3 for Bipolar Disorder: Meta-Analyses of Use in Mania and Bipolar Depression. J Clin Psychiatry. 2011;Online ahead of print.. 55. Tohen M, Zarate CA Jr, Hennen J, Khalsa HM, Strakowski SM, Gebre-Medhin P, et al. The McLeanHarvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry. Dec 2003;160(12):2099-107. [Medline]. 56. El-Mallakh RS. Medication adherence and the use of long-acting antipsychotics in bipolar disorder. J Psychiatr Pract. Mar 2007;13(2):79-85. [Medline]. Medscape Reference 2011 WebMD, LLC

http://emedicine.medscape.com/article/286342-overview

Page 10 of 10